Loading...
XHKG
0897
Market cap49mUSD
Jun 20, Last price  
0.34HKD
1D
-1.43%
1Q
-4.17%
Jan 2017
-9.21%
Name

Wai Yuen Tong Medicine Holdings Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
0.49
EPS
—
Div Yield, %
42.61%
Shrs. gr., 5y
-1.09%
Rev. gr., 5y
0.85%
Revenues
784m
-39.07%
326,909,000324,756,000381,266,000477,021,000496,151,000529,305,000639,512,000752,072,000808,517,000865,258,000831,088,000825,331,000738,440,000845,781,000751,443,000620,741,0001,108,565,0001,391,411,0001,286,428,000783,881,000
Net income
-15m
L-25.15%
-67,227,000-106,152,0009,923,00083,382,000-345,906,00045,797,00099,133,000-226,922,000148,433,000163,374,000120,979,00025,387,000-93,303,000-115,581,00074,627,000438,548,000-375,995,000-108,912,000-20,515,000-15,356,000
CFO
192m
+109.32%
-56,284,0005,073,000123,500,000-22,808,00016,864,00040,320,000-106,802,00033,724,000-9,884,00015,294,00052,787,000-115,661,000-89,867,000-76,731,000-26,633,0009,177,000358,490,000116,181,00091,578,000191,688,000
Dividend
Aug 22, 20240.147 HKD/sh

Profile

Wai Yuen Tong Medicine Holdings Limited, an investment holding company, manufactures, processes, and retails traditional Chinese medicines, Western pharmaceutical products, and health food and personal products in Hong Kong, Mainland China, Macau, and internationally. The company offers Chinese medicines and health food products under the Wai Yuen Tong brand name; and Western pharmaceutical and personal care products under the Madame Pearl's and Pearl's brands. It also engages in the investment, holding, and selling of properties; provision of financial services; and agricultural produce exchange market operation. As of March 31, 2022, the company operated 63 retail stores in Hong Kong. The company was founded in 1897 and is headquartered in Kowloon Bay, Hong Kong. Wai Yuen Tong Medicine Holdings Limited is a subsidiary of Rich Time Strategy Limited.
URL
https://www.wyth.net/
IPO date
Oct 31, 1997
Employees
1,941
Domiciled in
HK
Incorporated in
BM

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
783,881
-39.07%
1,286,428
-7.55%
Cost of revenue
745,832
1,200,276
Unusual Expense (Income)
NOPBT
38,049
86,152
NOPBT Margin
4.85%
6.70%
Operating Taxes
(6,359)
(15,283)
Tax Rate
NOPAT
44,408
101,435
Net income
(15,356)
-25.15%
(20,515)
-81.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
(14,728)
(9,960)
BB yield
5.11%
2.27%
Debt
Debt current
283,869
666,552
Long-term debt
375,320
1,098,066
Deferred revenue
65,605
Other long-term liabilities
51,220
798
Net debt
(104,908)
(2,181,971)
Cash flow
Cash from operating activities
191,688
91,578
CAPEX
(34,649)
(33,446)
Cash from investing activities
(84,621)
15,065
Cash from financing activities
(469,969)
(67,250)
FCF
877,628
7,470
Balance
Cash
196,781
625,006
Long term investments
567,316
3,321,583
Excess cash
724,903
3,882,268
Stockholders' equity
(42,404)
1,315,582
Invested Capital
2,039,149
4,042,370
ROIC
1.46%
2.51%
ROCE
1.90%
1.45%
EV
Common stock shares outstanding
1,181,346
1,216,213
Price
0.24
-32.22%
0.36
24.14%
Market cap
288,248
-34.17%
437,837
22.58%
EV
212,480
(404,941)
EBITDA
149,199
199,201
EV/EBITDA
1.42
Interest
40,792
106,306
Interest/NOPBT
107.21%
123.39%